Delving into the Latest Updates on QRX-3 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Eserenate, QRX-3

Target-

Action-

Mechanism-

Therapeutic Areas

Urogenital DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease

Active Indication

Chronic Kidney DiseasesKidney Tubular Necrosis, AcuteDiabetic Nephropathies+ [1]

Inactive Indication-

Originator Organization

Neukidney Inc.

Active Organization

Neukidney Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Start Date01 Oct 2025

Sponsor / Collaborator

Neukidney Inc.

NCT07161843

/ Not yet recruitingPhase 2/3

Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Start Date30 Aug 2025

Sponsor / Collaborator

Neukidney Inc.

NCT06948292

/ CompletedPhase 2

Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

Start Date01 Mar 2023

Sponsor / Collaborator

Neukidney Inc.

100 Clinical Results associated with QRX-3

Login to view more data

100 Translational Medicine associated with QRX-3

Login to view more data

100 Patents (Medical) associated with QRX-3

Login to view more data

100 Deals associated with QRX-3

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	United States	Neukidney Inc.	01 Oct 2025
Kidney Tubular Necrosis, Acute	Phase 3	United States	Neukidney Inc.	30 Aug 2025
Diabetic Nephropathies	Phase 2	United States	Neukidney Inc.	01 Mar 2023
Hypertensive Nephropathy	Phase 2	United States	Neukidney Inc.	01 Mar 2023